Alumis (NASDAQ:ALMS) Insider Roy Hardiman Sells 2,692 Shares

Alumis Inc. (NASDAQ:ALMS) insider Roy Hardiman sold 2,692 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.37, for a total value of $70,988.04. Following the transaction, the insider owned 207,746 shares in the company, valued at approximately $5,478,262.02. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Alumis Stock Performance

Shares of ALMS stock remained flat at $27.12 on Wednesday. The stock had a trading volume of 629,130 shares, compared to its average volume of 2,037,268. The firm has a market capitalization of $3.46 billion, a PE ratio of -13.70 and a beta of -0.69. The stock’s 50 day simple moving average is $25.26 and its 200-day simple moving average is $25.20. Alumis Inc. has a one year low of $3.76 and a one year high of $31.35.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The firm had revenue of $1.74 million for the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. Analysts anticipate that Alumis Inc. will post -2.87 EPS for the current year.

Institutional Trading of Alumis

Several hedge funds and other institutional investors have recently modified their holdings of ALMS. Handelsbanken Fonder AB bought a new stake in shares of Alumis in the second quarter valued at about $1,024,000. Stempoint Capital LP bought a new position in shares of Alumis during the first quarter worth about $5,057,000. Janus Henderson Group PLC acquired a new stake in Alumis in the 1st quarter valued at approximately $46,790,000. Ally Bridge Group NY LLC acquired a new stake in Alumis in the 1st quarter valued at approximately $3,678,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Alumis by 600.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 3,131 shares of the company’s stock valued at $69,000 after acquiring an additional 2,684 shares in the last quarter.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ALMS. Chardan Capital boosted their price target on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, May 19th. Wells Fargo & Company lifted their target price on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Morgan Stanley reissued an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research note on Friday, May 15th. Guggenheim lifted their price objective on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a report on Friday, May 15th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $25.00 price objective on shares of Alumis in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Alumis currently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.